Li Lieyou, Li Ganyang, Chen Huang, Feng Zhihai, Zhang Lin, Chen Lianglong, Fan Lin
Department of Cardiology, Fujian Medical University Union Hospital Institute of Coronary Heart Disease, Fuzhou, Fujian, People's Republic of China.
Department of Cardiology, Longyan First Hospital Affiliated with Fujian Medical University, Longyan, Fujian, People's Republic of China.
Diabetes Metab Syndr Obes. 2021 Dec 29;14:4931-4944. doi: 10.2147/DMSO.S339209. eCollection 2021.
Data are limited on the effect of diabetes mellitus (DM) on the prognosis of acute coronary syndrome (ACS) patients with heart failure with midrange ejection fraction (HFmrEF) who have undergone percutaneous coronary intervention (PCI). This study aimed to investigate the relationship between type 2 DM (T2DM) and 3-year outcomes in such a population.
A total of 377 ACS patients with HFmrEF (left ventricular EF 40%-49%) who had undergone PCI (132 diabetic and 245 nondiabetic patients) were included in the analysis. The primary outcome was a composite end point of all-cause death or HF rehospitalization. Cox proportional-hazard regression analysis and Kaplan-Meier tests were used to assess the effect of DM on the primary outcome. Sensitivity analysis was conducted with propensity score-matching analysis.
During a follow-up of 3 years, diabetic patients had higher incidence of the primary outcome than nondiabetic patients (96.1 vs 44.6 per 1,000 patient-years, incidence ratio 2.301, 95% CI 1.334-3.969; =0.002). Multivariate analysis showed that DM was associated with a significant increase in the composite outcome of all-cause death or HF rehospitalization (adjusted HR 2.080, 95% CI 1.115-3.878; =0.021). Sensitivity analysis further confirmed that DM was an independent prognostic factor of long-term adverse outcomes for ACS patients with HFmrEF who had undergone PCI (adjusted HR 3.792, 95% CI 1.802-7.980; <0.001).
Among ACS patients with HFmrEF who had undergone PCI, T2DM comorbidity was significantly associated with worse long-term outcomes.
关于糖尿病(DM)对接受经皮冠状动脉介入治疗(PCI)的射血分数中等范围的急性冠状动脉综合征(ACS)合并心力衰竭(HFmrEF)患者预后的影响,数据有限。本研究旨在调查此类人群中2型糖尿病(T2DM)与3年预后之间的关系。
分析纳入了377例接受PCI的HFmrEF(左心室射血分数40%-49%)的ACS患者(132例糖尿病患者和245例非糖尿病患者)。主要结局是全因死亡或因心力衰竭再次住院的复合终点。采用Cox比例风险回归分析和Kaplan-Meier检验评估糖尿病对主要结局的影响。进行倾向评分匹配分析的敏感性分析。
在3年的随访期间,糖尿病患者主要结局的发生率高于非糖尿病患者(每1000患者年96.1例 vs 44.6例,发生率比值2.301,95%CI 1.334-3.969;P=0.002)。多变量分析显示,糖尿病与全因死亡或因心力衰竭再次住院的复合结局显著增加相关(调整后HR 2.080,95%CI 1.115-3.878;P=0.021)。敏感性分析进一步证实,糖尿病是接受PCI的HFmrEF的ACS患者长期不良结局的独立预后因素(调整后HR 3.792,95%CI 1.802-7.980;P<0.001)。
在接受PCI的HFmrEF的ACS患者中,合并T2DM与更差的长期结局显著相关。